US · MTLS · SOFTWARE - APPLICATION
Materialise N.V. (MTLS) intrinsic value and stock valuation
$5.95as of 2026-11-21 · Mkt cap 401.11M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Materialise N.V. DCF and intrinsic value
InvestorsCraft values MTLS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MTLS’s statements →
Materialise N.V. Graham Number
Graham Number: $3.49d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $257.1M | $266.8M | $256.1M | $232M | $205.5M |
| Operating income | $4.94M | $9.43M | $5.62M | -$-2.87M | $12.2M |
| Net income | $7.41M | $13.4M | $6.72M | -$-2.12M | $13.2M |
| EPSd | $125.4K | $227.4K | $113.7K | -$-35.9K | $231.4K |
| Operating cash flow | $22.7M | $31.5M | $20.2M | $22.3M | $25.8M |
| Capital expenditure | -$-13.54M | -$-26.38M | -$-11.76M | -$-24.77M | -$-11.72M |
| Free cash flow | $9.14M | $5.08M | $8.4M | -$-2.48M | $14.1M |
| Total assets | $420.5M | $396.3M | $396.6M | $411.3M | $413.4M |
| Total debt | $66.2M | $41.3M | $64.4M | $81M | $99.1M |
| Net debt | -$-67.71M | -$-61.02M | -$-63.17M | -$-59.89M | -$-96.92M |
| Total equity | $255.4M | $248.5M | $236.6M | $228.9M | $232.6M |
| Cash and short-term investments | $133.9M | $102.3M | $127.6M | $140.9M | $196M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $257.1M | $266.8M | $256.1M | $232M | $205.5M |
| Cost of revenue | $110.2M | $115.9M | $111M | $103.3M | $87.3M |
| Gross profit | $146.9M | $150.8M | $145.1M | $128.8M | $118.2M |
| Research and development expenses | $44.3M | $44.4M | $38.1M | $37.6M | $26.9M |
| Selling, general and administrative expenses | $96.3M | $101.2M | $94.9M | $93M | $77.6M |
| Other expenses | $1.38M | -$-4.22M | $6.52M | $1.05M | $1.48M |
| Operating expenses | $142M | $141.4M | $139.5M | $131.6M | $106M |
| Cost and expenses | $252.1M | $257.3M | $250.5M | $234.9M | $193.2M |
| Interest income | $3.81M | $4.25M | $4.45M | $1.4M | $780K |
| Interest expense | $5.39M | $1.65M | $2.09M | $2.92M | $3.36M |
| Depreciation and amortization | $20.9M | $21.8M | $21.6M | $22.6M | $20.6M |
| Ebitda | $25.8M | $31.2M | $30.1M | $23.4M | $36.7M |
| Operating income | $4.94M | $9.43M | $5.62M | -$-2.87M | $12.2M |
| Total other income/expenses, net | $2.06M | $4.71M | $1.15M | $1.69M | $1.52M |
| Income before tax | $7M | $14.1M | $6.77M | -$-1.18M | $13.7M |
| Income tax expense | -$-410K | $730K | $80K | $970K | $590K |
| Net income | $7.41M | $13.4M | $6.72M | -$-2.12M | $13.2M |
| Weighted average shares outstanding | $59.1M | $59.1M | $59.1M | $59.1M | $56.7M |
| Weighted average diluted shares outstanding | $59.1M | $59.1M | $59.1M | $59.1M | $56.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $133.9M | $102.3M | $127.6M | $140.9M | $196M |
| Net receivables | $54.9M | $53.1M | $52.7M | $54.8M | $45.2M |
| Inventory | $14.9M | $17M | $17M | $15.4M | $10.8M |
| Total current assets | $223.5M | $190.5M | $206.5M | $216.4M | $257.8M |
| Property, plant and equipment, net | $118.2M | $119.1M | $103.5M | $102.7M | $93.5M |
| Goodwill and intangible assets | $68.8M | $73.4M | $74.6M | $82M | $50.4M |
| Long-term investments | $0.00 | $3.99M | $3.74M | $3.8M | $3.96M |
| Total non-current assets | $197M | $205.8M | $190.2M | $194.9M | $155.6M |
| Total assets | $420.5M | $396.3M | $396.6M | $411.3M | $413.4M |
| Accounts payable | $20.1M | $23.4M | $21.2M | $23.2M | $20.2M |
| Short-term debt | $10.3M | $13M | $25.5M | $20M | $21.2M |
| Deferred revenue | $43.5M | $46M | $40.8M | $41.7M | $33.3M |
| Total current liabilities | $91.8M | $102.2M | $105M | $106.1M | $91.4M |
| Long-term debt | $55.8M | $28.3M | $38.9M | $61M | $77.9M |
| Deferred revenue, non-current | $17.3M | $13.3M | $10.7M | $9.28M | $6.45M |
| Total non-current liabilities | $73.3M | $45.7M | $55.1M | $76.2M | $89.4M |
| Capital lease obligations | $3.06M | $7.73M | $7.94M | $8.05M | $8.62M |
| Total liabilities | $165.1M | $147.8M | $160M | $182.3M | $180.8M |
| Common stock | $4.49M | $4.49M | $4.49M | $4.49M | $4.49M |
| Retained earnings | $47.2M | $19M | $5.84M | -$-1.16M | $960K |
| Accumulated other comprehensive income (loss) | $0.00 | -$-9.08M | -$-7.63M | -$-8.27M | -$-6.75M |
| Total equity | $255.4M | $248.5M | $236.6M | $228.9M | $232.6M |
| Total investments | $0.00 | $3.99M | $3.74M | $3.8M | $3.96M |
| Total debt | $66.2M | $41.3M | $64.4M | $81M | $99.1M |
| Net debt | -$-67.71M | -$-61.02M | -$-63.17M | -$-59.89M | -$-96.92M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $7.41M | $13.4M | $6.58M | -$-2.15M | $13.1M |
| Depreciation and amortization | $20.9M | $21.8M | $21.6M | $22.6M | $20.5M |
| Stock-based compensation | $0.00 | $280K | $40K | -$-140K | -$-1.04M |
| Change in working capital | -$-8.49M | -$-1.42M | -$-12.58M | $1.02M | -$-5.89M |
| Accounts receivable | -$-2.57M | -$-1.04M | -$-3.27M | -$-6.33M | -$-10.92M |
| Inventory | -$-870K | -$-370K | -$-790K | -$-5.01M | -$-1.42M |
| Accounts payable | -$-4.81M | $0.00 | -$-8.78M | $0.00 | $6.45M |
| Net cash provided by operating activities | $22.7M | $31.5M | $20.2M | $22.3M | $25.8M |
| Investments in property, plant and equipment | -$-15.62M | -$-24.65M | -$-9.23M | -$-21.61M | -$-11.72M |
| Acquisitions, net | $370K | -$-2.67M | $0.00 | -$-29.29M | -$-880K |
| Net cash used for investing activities | -$-9.32M | -$-28.59M | -$-11.04M | -$-53.86M | -$-13.13M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $20K | $88.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $18M | -$-27.64M | -$-22.37M | -$-22.51M | $71.2M |
| Net change in cash | $43.7M | -$-25.27M | -$-13.29M | -$-55.16M | $84.5M |
| Cash at end of period | $133.9M | $102.3M | $127.6M | $140.9M | $196M |
| Operating cash flow | $22.7M | $31.5M | $20.2M | $22.3M | $25.8M |
| Capital expenditure | -$-13.54M | -$-26.38M | -$-11.76M | -$-24.77M | -$-11.72M |
| Free cash flow | $9.14M | $5.08M | $8.4M | -$-2.48M | $14.1M |
Line items
Line items
Line items
About Materialise N.V.
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
- CEO
- Brigitte de Vet-Veithen
- Employees
- 2.56K
- Beta
- 1.32
Explore
Frequently asked questions
What is the intrinsic value of Materialise N.V. (MTLS)?
Materialise N.V. (MTLS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MTLS undervalued?
MTLS trades at a price of $5.95 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.